eXIthera Pharmaceuticals

company

About

ExIthera Pharmaceuticals supports the creation of antithrombotic and stroke prevention medications.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$2M
Industries
Biotechnology,Genetics,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2M
eXIthera Pharmaceuticals has raised a total of $2M in funding over 2 rounds. Their latest funding was raised on Aug 2, 2012 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 2, 2012 Series A $2M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
eXIthera Pharmaceuticals is funded by 1 investors. Access BridgeGap Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Access BridgeGap Ventures Series A